NITRO-DUR 0.2 0.2 MG
NITROGLYCERIN : 0.2 MG · DIN 01911910 · USPHARMA LTD
Health Canada status: MARKETED
What is NITRO-DUR 0.2?
NITRO-DUR 0.2 0.2 MG contains NITROGLYCERIN : 0.2 MG. It is listed in the Health Canada Drug Product Database under DIN 01911910, held by USPHARMA LTD, supplied as PATCH (EXTENDED RELEASE) for TRANSDERMAL administration. Health Canada currently lists it as marketed, status dated 12-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NITRO-DUR 0.2 used for?
NITRO-DUR (nitroglycerin) used intermittently is indicated for the prevention of anginal attacks in patients with stable angina pectoris associated with coronary artery disease. It can be used in conjunction with other antianginal agents such as beta-blockers and/or calcium antagonists. NITRO-DUR is not intended for the immediate relief of acute attacks of angina pectoris. Sublingual nitroglycerin preparations should be used for this purpose.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01911910 |
|---|---|
| Brand name | NITRO-DUR 0.2 |
| Generic / active ingredient | NITROGLYCERIN : 0.2 MG |
| Manufacturer | USPHARMA LTD |
| Strength | 0.2 MG |
| Dosage form | PATCH (EXTENDED RELEASE) |
| Route of administration | TRANSDERMAL |
| Schedule | Ethical |
| ATC code | C01DA02 GLYCERYL TRINITRATE |
| AHFS class | 24:12.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Jul-2018 |
| Original market date | 1991-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 01911910 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1911910 |
| Brand name | NITRO-DUR 0.2 |
| Active ingredient / INN | NITROGLYCERIN : 0.2 MG |
| ATC code | C01DA02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01 |
| AHFS class | 24:12.08 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | USPHARMA LTD |
How is it stored and handled?
null
How is it supplied?
null
Which pack is which?
| Strength on the label | 0.2 MG |
|---|---|
| Dosage form | PATCH (EXTENDED RELEASE) |
| Route | TRANSDERMAL |
| Packaging as described in the monograph | null |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code C01DA02 GLYCERYL TRINITRATE. 18 of 39 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYLAN-NITRO PATCH 0.2 | 0.2 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02407442 |
| MYLAN-NITRO PATCH 0.4 | 0.4 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02407450 |
| MYLAN-NITRO PATCH 0.6 | 0.6 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02407469 |
| MYLAN-NITRO PATCH 0.8 | 0.8 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02407477 |
| NITRO-DUR 0.4 | 0.4 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | DIN 01911902 |
| NITRO-DUR 0.6 | 0.6 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | DIN 01911929 |
| NITRO-DUR 0.8 | 0.8 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | DIN 02011271 |
| NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02145308 |
| NITROGLYCERIN IN 5% DEXTROSE INJ.-400MCG/ML | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02145316 |
| NITROJECT | 50 MG / 10 ML | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 00778869 |
Who else supplies GLYCERYL TRINITRATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GLYCERYL TRINITRATE appears in 68 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.